StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) stock

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.40+0.06 (+0.42%)

Close on Nov 17, 2026Market cap $979.40MP/E –Yield –

Jade Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Jade Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was -$130.30M. For fiscal 2025 it was -$94.69M. The highest annual figure on record is -$7.86M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$94.69M–
FY2024Dec 31, 2024-$71.20M–
FY2023Dec 31, 2023-$56.78M–
FY2022Dec 31, 2022-$39.12M–
FY2021Dec 31, 2021-$27.40M–
FY2020Dec 31, 2020-$7.86M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$28.91M–
Q2 FY2026Jun 30, 2026-$43.66M–
Q1 FY2026Mar 31, 2026-$24.08M–
Q4 FY2025Dec 31, 2025-$33.65M–
Q3 FY2025Sep 30, 2025-$22.12M–
Q2 FY2025Jun 30, 2025-$20.16M–
Q1 FY2025Mar 31, 2025-$18.76M–
Q4 FY2024Dec 31, 2024-$11.05M–
Q3 FY2024Sep 30, 2024-$16.04M–
Q2 FY2024Jun 30, 2024-$20.43M–
Q1 FY2024Mar 31, 2024-$23.67M–
Q4 FY2023Dec 31, 2023-$14.80M–
Q3 FY2023Sep 30, 2023-$15.61M–
Q2 FY2023Jun 30, 2023-$14.94M–
Q1 FY2023Mar 31, 2023-$11.42M–
Q4 FY2022Dec 31, 2022-$14.87M–
Q3 FY2022Sep 30, 2022-$9.72M–
Q2 FY2022Jun 30, 2022-$8.88M–
Q1 FY2022Mar 31, 2022-$5.66M–
Q4 FY2021Dec 31, 2021-$13.09M–
Q3 FY2021Sep 30, 2021-$6.53M–
Q2 FY2021Jun 30, 2021-$4.01M–
Q1 FY2021Mar 31, 2021-$3.78M–
Q4 FY2020Dec 31, 2020-$2.88M–
Q3 FY2020Sep 30, 2020-$2.43M–

More Jade Biosciences figures

See a number that looks wrong?